Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | XIAP | P98170 | 5/20 | 0.40 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | CCKBR | P32239 | 2/20 | 0.37 |
| ▸ | CCKAR | P32238 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201757 | 0.81 | NOTUM (0.40) | CYP3A4XIAPACEABCB11AGTR2 | |
| SCHEMBL10201755 | 0.78 | XIAP (0.43) | CYP3A4XIAPCASP1 | |
| SCHEMBL645106 | 0.76 | CASP1 (0.52) | CYP3A4XIAPCASP1CCKBR | |
| SCHEMBL646039 | 0.74 | CASP1 (0.50) | CYP3A4XIAPCASP1CCKBR | |
| SCHEMBL645174 | 0.73 | CASP1 (0.49) | CYP3A4XIAPCASP1CCKBR | |
| SCHEMBL6175353 | 0.73 | SCN9A (0.46) | CYP3A4XIAPCCKBR | |
| SCHEMBL10201800 | 0.72 | ACE (0.47) | CYP3A4XIAPACEABCB11AGTR2 | |
| SCHEMBL13140305 | 0.72 | XIAP (0.46) | CYP3A4XIAPCASP1CCKBR | |
| SCHEMBL6179478 | 0.71 | CCKBR (0.44) | CCKBR | |
| SCHEMBL645107 | 0.70 | XIAP (0.46) | CYP3A4XIAPCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CYP3A4 2587/4885XIAP 257/4885ACE 16/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CYP3A4 2587/4885XIAP 257/4885ACE 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.